Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis

The IMpower trials reported significant effects of atezolizumab‐containing chemotherapies on Caucasian patients. Chinese patients differ from their Western counterparts in terms of driver mutations, etiologies, and regimen tolerance. In China, atezolizumab‐containing chemotherapies are not cost‐effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yingkai, Kang, Shizhou, Yan, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107600/
https://www.ncbi.nlm.nih.gov/pubmed/35568997
http://dx.doi.org/10.1002/prp2.941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107600/
https://www.ncbi.nlm.nih.gov/pubmed/35568997
http://dx.doi.org/10.1002/prp2.941

Ejemplares similares